In terms of DPP4 inhibitors, in 2006, Merck's original research of Sitagliptin was launched, Novartis Vildagliptin was launched in 2007, Saxagliptin, jointly developed by Bristol Myers Squibb and AstraZeneca, was launched in 2009, Takeda Alogliptin was launched in 2010, and so on
By influencing appetite and reducing caloric intake, Ozempic helps patients manage their weight
Epistaxis is a common occurrence in the general population, with approximately 60% of people experiencing at least one nosebleed during their lifetime
8 Among healthy older adults, a 30 mL/day blueberry concentrate intervention for 12 weeks improved cerebral blood flow and enhanced activity in brain regions essential for memory and executive function
The addition of glucagon receptor agonism increases energy expenditure and drives liver fat reduction
This reinforces the importance of viewing semaglutide as part of a broader health strategy rather than a quick fix